In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to announce the launch in Israel of UTIPRO® PLUS, our product for uncomplicated Urinary Tract Infections. The product is distributed by our long term partner Lapidot.
Utipro® Plus is a medical device intended for the control and prevention of urinary tract infections produced by pathogens such as E.coli and other gram (-) bacteria normally involved in the etiology of urological infections.
Utipro® Plus has been presented to HCP and available as capsules for oral administration in pharmacies all across the Israeli territory since Q4 2017.
Utipro® Plus is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Noventure SL)
We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Tasectan® Duo´s second market, after the successful introduction in Italy by Angelini.
Tasectan Duo ® is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish the physiological functions of the gut barrier, as well as to prevent dysbiosis.
It is intended for prolonged diarrhea (lasting between 1 - 2 weeks) or for the prevention and management of diarrhea associated with antibiotic treatment, and is expected to capture part of the market space of probiotics used for diarrhea.
“The new mucoprotectants, such as gelatin tannate and xyloglucan, have the ability to protect the intestinal mucosa and to exert anti-diarrheal effects. In the future the ability of these substances to enhance the intestinal barrier may extend their use in the management of a variety of gastro-intestinal diseases associated with ‘leaky gut’.
